AIO-Studien-gGmbH
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2017-10-23
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 103
- Registration Number
- NCT03317457
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-10-10
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 12
- Registration Number
- NCT03305913
- Locations
- 🇩🇪
Universitätsmedizin Mainz, I.Medizinische Klinik und Poliklinik, Mainz, Germany
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 169
- Registration Number
- NCT03219775
- Locations
- 🇦🇹
Univ. Klinik für Innere Medizin, Graz, Austria
🇦🇹Ordensklinikum Linz - KH Barmherzige Schwestern, Linz, Austria
🇦🇹Universitätsklinikum Salzburg, Salzburg, Austria
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 30
- Registration Number
- NCT03197467
- Locations
- 🇩🇪
Universitätsklinikum Heidelberg, Heidelberg, Germany
Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers
- Conditions
- Interventions
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 47
- Registration Number
- NCT03193931
- Locations
- 🇩🇪
Medizinsche Hochschule Hannover, Hannover, Germany
Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2022-09-29
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 43
- Registration Number
- NCT03174405
- Locations
- 🇩🇪
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-02-07
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 93
- Registration Number
- NCT03044587
- Locations
- 🇩🇪
Universitätsklinikum Ulm, Ulm, Germany
Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC
- First Posted Date
- 2017-02-07
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 101
- Registration Number
- NCT03044626
- Locations
- 🇩🇪
DRK Kliniken Berlin Mitte, Berlin, Germany
🇩🇪Evangelische Lungenklinik Berlin, Berlin, Germany
🇩🇪Krankenhaus Nordwest, Frankfurt / Main, Germany
Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 100
- Registration Number
- NCT03043547
- Locations
- 🇩🇪
Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Germany
mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 119
- Registration Number
- NCT03043729
- Locations
- 🇩🇪
Tagestherapiezentrum am ITM & III. Med. Klinik, Mannheim, Germany